Labopharm Inc.
480 Armand-Frappier Boulevard
Laval,
QC H7V 4B4
Phone: 450-686-1017
Fax: 450-686-9141
Web Site: http://www.labopharm.com
| REUTERS ABRIDGED BUSINESS SUMMARY | |
| Labopharm Inc., a specialty pharmaceutical company, develops drugs by incorporating its proprietary controlled-release technologies. It offers once-daily formulation of the analgesic tramadol under the RYZOLT brand name for the treatment of severe chronic pain in adults. The company sells RYZOLT primarily in the United States, Europe, Canada, South Korea, and Australia. Labopharms products in pipeline include once-daily formulation of trazodone, a serotonin antagonist reuptake inhibitor for the treatment of depressive disorder. Its product candidates in clinical development based on Contramid platform comprise twice-daily formulation of tramadol plus acetaminophen to address acute pain; and Abuse Deterrent Platform to provide safer medications through resistance to the uncontrolled release of the active ingredient after actions, such as breaking, chewing, crushing and heating, or consumption with alcohol. Its product candidates in clinical development based on the Polymeric Nano-Delivery System platform comprise lipid-and preservative-free formulation of the intravenous anaesthetic agent propofol; and SN-38, which is the active metabolite in the prescribed intravenous colon cancer drug irinotecan. Labopharm was formerly known as Centre de recherche appliquee pharmaceutique CRAP inc. and changed its name to Labopharm Inc. in September 1994. The company was founded in 1990 and is headquartered in Laval, Canada. |
|
| Key Statistics | More from Reuters
Expanded Business Description |
| |
| REUTERS ABRIDGED FINANCIAL SUMMARY | |
| | Pay | Exercised | Mr. James R. Howard-Tripp ,
Chief Exec. Officer, Pres, Director, Chairman of Labopharm Europe Limited, Chief Exec. Officer of Labopharm Europe Limited and Pres of Labopharm Europe Limited |
N/A
| N/A | Mr. Mark A. D'Souza , 48
Chief Financial Officer and Sr. VP |
$
357.00K | N/A | Ms. Mary Anne Heino ,
Pres of Labopharm USA Inc. |
$
382.00K | N/A | Dr. Damon C. Smith BSc, Ph.D.,
Sr. VP of R&D |
N/A
| N/A | Mr. Tony Playle ,
Managing Director of Labopharm Europe Limited |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.02 (1.06%)
Reuters offers more in-depth
